Study-specific differences in method of assessment and cut points for hormone receptor and ERBB2/HER2 status of breast cancer, given that these data were frequently obtained from medical records, may have led to differential classification of the tumor types between studies, potentially leading to underestimation of relative risks. This evidence concerns the gene NR4A1 and breast cancer.